News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Spain’s Zeltia Says Latest Yondelis Results Hopeful
November 22, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Nov 22 (Reuters) - Spanish chemicals and biotech company Zeltia (ZEL.MC: Quote, Profile, Research) said on Tuesday recent tests with its marine based anti-cancer drug Yondelis had shown positive results.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Psychedelics
Final psychedelics guidance suggests FDA is ‘receptive’ to helping companies succeed
July 14, 2026
·
3 min read
·
Michael Gibney
Huntington’s disease
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
July 13, 2026
·
4 min read
·
Heather McKenzie
Insights
From sequence to scale: Gene editing’s new era in biologics manufacturing
July 10, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Antibody-drug conjugates
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
July 10, 2026
·
1 min read
·
Gabrielle Masson
